Genomic Diversity of the SARS-CoV-2 in Turkey and the Impact of Virus Genome Mutations on Clinical Outcomes

Ilker Karacan^{1,2†}, Tugba Kizilboga Akgun^{1†}, Nihat Bugra Agaoglu^{1,3}, Payam Zolfagharian¹, Mehtap Aydin⁴, Gizem Alkurt¹, Jale Yildiz¹, Betsi Kose¹, Nisan Denizce Can⁵, Ayse Serra Ozel⁴, Nilsun Altunal⁴, Arzu Irvem⁶, Yasemin Kendir Demirkol⁷, Ozlem Akgun Dogan⁷, Levent Doganay^{1,8*}, Gizem Dinler Doganay^{1,5*}

¹ Genomic Laboratory (GLAB), Umraniye Training and Research Hospital, University of Health Sciences, Istanbul, Turkey

² Science and Advanced Technology Research Center, Istanbul Medeniyet University, Istanbul, Turkey

³ Department of Medical Genetics, Umraniye Training and Research Hospital, University of Health Sciences, Istanbul, Turkey

⁴ Department of Infectious Diseases and Clinical Microbiology, Umraniye Training and Research Hospital, University of Health Sciences, Istanbul, Turkey

⁵ Department of Molecular Biology and Genetics, Istanbul Technical University, Istanbul, Turkey

⁶ Department of Microbiology, Umraniye Training and Research Hospital, University of Health Sciences, Istanbul, Turkey

⁷ Department of Pediatric Genetics, Umraniye Training and Research Hospital, University of Health Sciences, Istanbul, Turkey

⁸ Department of Gastroenterology, Umraniye Training and Research Hospital, University of Health Sciences, Istanbul, Turkey

† These authors contributed equally.

*These authors have equal correspondence.

Corresponding authors:

Gizem Dinler Doganay, Ph.D. Molecular Biology and Genetics Department, Istanbul Technical University, Istanbul, Turkey. e-mail: gddoganay@itu.edu.tr

Levent Doganay, MD. Genomic Laboratory (GLAB), Umraniye Training and Research Hospital, University of Health Sciences, Istanbul, Turkey. e-mail: levent.doganay@saglik.gov.tr

35 **Summary**

36 COVID-19 is a viral respiratory disease caused by SARS-CoV-2 infection. Global efforts of
37 genomic surveillance of the virus give chance to track the spread of the pandemic. Global
38 emergence of some viral mutations called attention and various studies have been suggested
39 about increased infectivity of the virus. Herein, we sequenced viral genomes isolated from
40 184 patients in Istanbul and analyzed clinical metadata for the investigation of any viral
41 mutation which affects the disease course of the host. We did not detect any viral mutations
42 affecting the disease outcome in our cohort. Besides, we observed intra-host mutations in
43 76% of the isolates. Insertion/deletion and stop-gain mutations are also significantly less
44 common among intra-host variants compared to consensus viral genome mutations.
45 Longitudinal genomic surveillance is essential for timely detection of any lineages that might
46 affect clinical outcome, the performance of diagnostic assays, or even the immunological
47 escape of the virus.

48

49 **Keywords:** SARS-CoV-2, COVID-19, genome diversity, mutation, intra-host mutation

50

51 **Introduction**

52 Since the first case at the end of 2019, the novel betacoronavirus SARS-CoV-2 has spread the
53 world rapidly by reaching more than 60 million affected people and 1.4 million deaths as of
54 November 2020. Host response to SARS-CoV-2 infection and clinical severity can show high
55 heterogeneity. While many cases do not show any symptoms, some COVID-19 patients
56 develop acute respiratory distress syndrome and other life-threatening symptoms such as
57 pulmonary edema or thrombotic coagulopathy (Huang et al., 2020). Older age, cardiovascular
58 disease, respiratory diseases, diabetes are among known risk factors for COVID-19 clinical
59 course (Jordan et al., 2020; Wu and McGoogan, 2020). Pathogenesis of the COVID-19 is still
60 poorly understood but older age, male sex, and several other factors have been shown
61 associated with increased mortality rates (Li, X. et al., 2020; Zhou et al., 2020). Evidence on
62 multisystemic involvement of the disease provoked questions on the association between host
63 genetic factors with clinical outcome (Initiative, 2020; Zeberg and Paabo, 2020). Host genetic
64 factors and their pathogenesis in disease severity is still needed to be elucidated.

65 It has been known that RNA viruses have a much higher mutation rate, which can provide
66 enhanced adaptation and virulence, compared to DNA viruses (Duffy, 2018; Luring and
67 Andino, 2010). Mutations in the RNA-based genome of coronaviruses can arise due to
68 replication errors which may be reduced in coronaviruses due to their polymerases with

proofreading mechanism (Minskaia et al., 2006; Snijder et al., 2003). Also, the RNA editing mechanism, which is a part of the host immunity, can trigger new mutation events in the viral genome (Harris and Dudley, 2015; Mangeat et al., 2003). Global efforts for sequencing SARS-CoV-2 genomes revealed that may be expected for a coronavirus, genome diversity is very low (Fauver et al., 2020). However, excessive global spreading can give the virus a chance for a natural selection of advantageous mutations resulting in increased infectivity. High throughput sequencing methods have been progressively used during the COVID-19 outbreak. Extensive viral genome analyses by laboratories all over the world have reached the identification of more than 225,000 records in the GISAID SARS-CoV-2 database in just one year. In the meantime, several questions about viral mutations and their effects on the patient's clinical outcomes have arisen. Recent studies claimed increased infectivity or fatality rates caused by a viral p.D614G mutation of spike protein (Becerra-Flores and Cardozo, 2020; Korber et al., 2020; Li, Q. et al., 2020). The p.D614G mutation, which is now dominating the global pandemic, has shown that it was present in retrospectively-sampled isolates in China in late January (Volz et al., 2020). However, there is not any consensus and solid evidence on the effects of this mutation in terms of infectivity or mortality rates among patients due to uncertainty whether the frequency of this mutation is caused by chance or natural selection (Grubaugh et al., 2020). A global and continuous effort is needed for viral strain monitoring to detect any mutation which may lead to higher mortality or infectivity rate. In this study, we sequenced 184 viral genomes sampled mostly in Istanbul, between the 13th of April and the 24th of June 2020. All related clinical data has been collected and viral genome mutations were tested for any association with the patient's clinical outcome.

Methods

Patients and clinical evaluation: All patients enrolled in the study evaluated with the criteria defined by 'COVID-19 Diagnosis and Treatment Guide' published by the Turkish Ministry of Health. We grouped the patients as asymptomatic, mild, or severe according to the following conditions:

1. Asymptomatic: Patients without any clinical, radiological symptoms or any signs of the disease.
2. Mild: Patients with mild symptoms had respiratory symptoms such as cough and dyspnea, fever, headache, sore throat, runny nose, muscle and joint pain, extreme weakness, alteration in sense of smell and taste, diarrhea.

3. Severe: Patients with severe symptoms had (1) respiratory rate ≥ 30 breaths/min; (2) $\text{SpO}_2 \leq 93\%$ while breathing room air; (3) $\text{PaO}_2/\text{FiO}_2 \leq 300$ mmHg; (4) respiratory failure which requires mechanical ventilation; (5) shock; (6) combined with other organ failures, need to be admitted to ICU.

Viral RNA extraction, genome sequencing, and data analysis: Viral RNA extraction, library preparation, and sequencing were performed as described previously (Karacan et al., 2020). Briefly, RNA was extracted from nasopharyngeal swab samples using the High Pure Viral RNA Kit (Roche Life Science). The sequencing library was prepared with multiplexed PCR based target enrichment using CleanPlex SARS-CoV-2 Library Preparation Kit (Paragon Genomics Inc). Pooled libraries were sequenced on the Illumina NextSeq500 instrument.

Raw sequencing data were first demultiplexed and quality assessment was performed using the FASTQC program (Andrews, 2010). Adapter sequences were trimmed using cutadapt (Martin, 2011) and reads were aligned to the reference SARS-CoV-2 genome (NC_045512.2) using bwa-mem (Li, 2013). Primers were pruned using TrimPrimers script within the fgbio tool (<http://fulcrumgenomics.github.io/fgbio/>). Variant calling and consensus sequence generation were performed using Samtools (Li et al., 2009) and iVar (Grubaugh et al., 2019). Alternate bases with 10% frequency were called as variants and consensus sequences were generated for major alleles with at least 10x depth of coverage. Variant files for each isolate were converted to vcf files, which was further processed with BCFtools (Li, 2011) and annotated using ANNOVAR (Wang et al., 2010). Consensus genome sequences of isolates were aligned using MAFFT (Katoh et al., 2019). The neighbor-joining method was used to estimate phylogenies using aligned sequences and the tree was visualized using FigTree v1.4.4. Clade annotations were performed using Nextclade tool (<https://clades.nextstrain.org>).

Statistical analysis: Descriptive statistics were used to present clinical data. Proportions and percentages were used for the categorical data and mean values and standard deviations were used for the continuous data. Statistical significance of categorical data was calculated by two-tailed Fisher's exact test. A value of $p < 0.05$ was considered statistically significant.

Results

Samples were collected from 184 patients in Turkey between the 13th of April and the 24th of June 2020. The majority of the samples were collected from Istanbul, the epicenter of the pandemic in Turkey. Overall, the study cohort includes 14 patients (8%) who did not

manifest any symptoms, 65 patients (37.6%) have at least one comorbidity. Most of the patients (n=128, 73.1%) have a mild disease course. Detailed clinical features of enrolled patients were presented in Table 1.

Common viral variants and genetic phylogeny: Prepared amplicon libraries were sequenced on a NextSeq 500 instrument with an average output of 1.29 ± 0.64 million reads per sample resulting in an average of $5,212 \pm 3,931$ depth of coverage. In total, 316 different nucleotide mutations were detected with an average count of 10.33 per sample. Among analyzed viral isolates, 175 were non-synonymous, 116 were synonymous, 16 were non-coding, six were insertion/deletion, and three were stop-gain mutations. The most predominant mutation was C>U transition which came up to 52.37% of total conversion. The most frequent mutation among 184 isolates and their consequences on the genome was given respectively in Table 2. Positions 241, 23403, 3037, and 14408 were found to harbor the highest mutation which reoccurred in almost 97% of viral isolates in this study. Clade assignment based on Nextstrain nomenclature showed that the most common clades were 20B (59.8%) and 20A (33.7%) whereas 19A (4.3%) and 20C (2.2%) were in the minority (Figure 1).

Viral clades and mutations are not associated with clinical outcome: Moreover, we compared the clinical findings of patients to the viral genome mutations and Nextstrain clades. We selected two clades (20A and 20B) due to obtaining enough sampling in our cohort and compared the clinical manifestations of the patients. As a result, patients infected by these two virus clades showed similar clinical features. Similarly, we found no statistical difference between viral genome mutations which were detected in at least 10 patients, and clinical severity, intensive care unit needs, and being asymptomatic. These results showed that commonly seen viral mutations and clades are not associated with clinical manifestations of patients in this study. Of note, the p.Q57H variant in the ORF3a gene has a significantly higher frequency in females (79.8%) compared to males (66%) with a p-value of 0.0472. Conversely, GGG to AAC trinucleotide change at positions 28881-28883 located in the N gene has been detected more frequently in males (48%) compared to females (30.9%) with a p-value of 0.0236. A complete list of tested variants and clinical parameters was given in Table 3.

Possibly detrimental intra-host mutations are under negative selection: We generated consensus sequences of each isolate considering the major alleles (>50% of all reads) for genomic positions. Variant calling using NGS data revealed that 140 isolates (76%) have polymorphic sites in which minor allele frequencies (MAF) range between 10-90%. The rest of the samples have mutations only whose allelic frequency was over 90%. We further focused on those polymorphic sites for the presence of any association to clinical parameters. However, we could not detect any significant association between the number of polymorphic variations and clinical data. Overall, we identified 430 polymorphic sites in this study, and 95 (22.1%) of them were detected in at least two patients or identical to a consensus variant.

Further, we inspected those intra-host mutations for their occurrence events among isolates. Insertion and deletion mutations together with stop-gain mutations were more frequent in intra-host mutation events with statistical significance whereas non-coding variants were seen less in intra-host mutation events (Table 4). The overall frequencies of synonymous and non-synonymous mutation events were found not to be statistically significant between intra-host and consensus mutations. We also compared intra-host mutation counts to the clinical manifestations of the patients and no significant difference was detected.

Discussion

SARS-CoV-2, which is an RNA virus, is spreading globally at an unprecedented speed. Naturally, it evolves and some mutations which may alter its virulence or infectivity can be expected. High throughput sequencing capacity of laboratories together with experiences with other pathogens give the research community the ability to follow-up this rapidly expanding infection closely. Genomics based viral outbreak monitoring gives chance to investigate transmission dynamics and clinical impact of mutations (Alm et al., 2020). Besides, chasing viral strains in the populations is very important not only observing local or global spread but also tracing any mutation that may worsen the clinical outcomes or creating the risk of vaccine escape in the future, too. The majority of the naturally occurring mutations are expected to be neutral but some may provide advantageous or deleterious to the pathogen. Deleterious mutations that result in decreased infectivity will quickly disappear; inversely advantageous mutations are possible to reach high frequency in the population. Of note, deciding whether a mutation is neutral or advantageous during a global pandemic can be sophisticated due to founder effect or sampling bias (Liu et al., 2020; Mavian et al., 2020; van Dorp et al., 2020). Herein, we analyzed whole-genome sequences of 184 SARS-CoV-2

isolates in Istanbul which was the epicenter of the pandemic in Turkey, using a high throughput sequencing method. We evaluated viral genomic changes for any association with the clinical outcomes of the patients.

A recent study pointed out that the majority of the analyzed samples in the European region consisted of 20A and 20B clades according to Nextstrain nomenclature (Alm et al., 2020). Similar to the European genomic surveillance study, 93.5% of samples analyzed in this work mostly belonged to the 20A or 20B clades. Isolates belonging to the 19A and 20C clades constituted 4.3% and 2.2% of all samples, respectively. Overall, we revealed that clade distribution in Istanbul was highly similar to that in Europe. Considering the pandemic outbreak in Turkey, it can be stated that the early introduction of the virus to Istanbul originated from Europe.

There have been criticisms of viral genetic differences and their effects on clinical outcomes of infected patients. Recent studies were unable to find any association between the clinical features of patients and viral mutations or clades. Even if there is a possibility for an arising mutation with potential pathological effects, there is not enough evidence to support this hypothesis, yet. Zhang et al. reported that major lineages among virus isolates have no major difference in clinical outcomes (Zhang et al., 2020). In this study, we are also unable to detect any genetic changes among sequenced viral genomes which may cause different clinical outcomes in terms of severity of the disease or manifesting symptoms. On the other hand, studies are suggesting viral genetic changes such as p.D614G mutation may play a role in pathogenicity or transmissibility (Hou et al., 2020; Korber et al., 2020). However, extensive genomic and functional studies are still needed to prove those findings. Together with some reports on the effects of p.D614G, the reason is still not known clearly whether this mutation became dominant due to evolutionary advantages, founder effect, or possible sampling bias in the western world (Grubaugh et al., 2020). Our dataset was underpowered to test any association between clinical manifestations and p.D614G mutation since more than 95% of our samples have this mutation.

Studies on SARS-CoV-2 genome variants are mainly focused to understand viral epidemiology, transmission dynamics, development of diagnostic assays, vaccines, and drugs. It is very difficult to determine the origins of each kind of genomic alteration, but large proportions of SARS-CoV-2 genome alterations are C>U changes (Matyasek and Kovarik, 2020; Simmonds, 2020). This type of nucleotide change was shown to be mainly caused by host RNA-editing mechanisms, namely ADAR and APOBEC deaminase mechanisms, as a part of the host antiviral defense mechanism (Di Giorgio et al., 2020). In our data, 52.39% of

all conversions are C>U transitions. Since the deamination in humans is known to be a driver of mutational events and associated with a variety of diseases, clinical outcomes of COVID-19 patients might also be associated with this antiviral defense mechanism.

During the SARS-CoV-2 pandemic, high throughput sequencing has been globally used for viral genome analysis to uncover transmission patterns and evolutionary dynamics of the virus. Thus, this pandemic was the first in which researchers were able to continuously track genomic changes. Inter-host consensus sequences of the pathogen genome are always used for epidemiological investigations. However, these consensus sequences ignore the intra-host genomic variations of the virus population within the host. Besides all mutation events originated from an intra-host mutation, monitoring those events is also crucial to study its evolution dynamics. These intra-host variations of the virus genome may cause the immunological escape of the virus or affect the diagnostic performance of molecular assays. High-quality data of the deep sequencing methodologies give an opportunity to sensitively detect intra-host variations with minor allele frequencies (MAF) as low as 5%. In this study, we detected a total of 430 intra-host unique mutations with MAF between 10-90% in 76% of all samples. Our results indicated that subclonal mutations of the SARS-CoV-2 genome are prevalent among clinical samples. Also, 22.1% of those unique mutations occurred in at least two patients or identical to a consensus variant. This also indicates that the majority of those mutational events are not localized in hotspot sites.

Our results were highly similar to Rose et al. who reported intra-host mutations in 72% of analyzed 406 isolates (Rose et al., 2020). Of note, the number of intra-host variation events was not comparable since the conditions for the definition of polymorphic is not clear in the preprint article by Rose et al. whereas we used intra-host mutation definition if MAF was between 10% and 90% for a called variant.

A closer look at these polymorphic sites revealed that frequencies of non-synonymous and synonymous variants were not statistically different than inter-host variations (MAF > 90%) in the cohort. Whereas frequencies of stop-gain, in/del, and noncoding variants differ between intra- and inter-host variations. Stop-gain and in/del mutations were observed more in intra-host variations compared to inter-host consensus variants with MAF >90%. Insertion and deletions were detected at 5% and 0.9% in all intra- and inter-host variants, respectively. Similarly, the stop-gain variation rate in inter-host variations was 0.12% whereas its frequency in inter-host variations was ten times more: 1.2%. This result may be due to possible detrimental effects of those mutations by reducing viral activity.

Even though polymorphic sites might also be caused by amplification or sequencing errors, detection of those variants with different sequencing methodologies indicates the presence of intra-host variants. We also considered if these intra-host variations were caused by mixed infections but there is not any statistical difference in the occurrence of intra-host variations between outpatient and hospitalized groups. Further investigations about intra-host mutations are still required for understanding SARS-CoV-2 genome dynamics. To conclude, our results were not able to identify any significant SARS-CoV-2 mutation related to the patient's clinical manifestations or severity of the disease at this stage. Besides, we report mostly unique intra-host mutations in 76% of the samples with MAF ranging between 10-90 %, indicating continuous intra-host mutational events are very common. Since those mutations might be an origin for a lineage causing immunological escape of the virus, further longitudinal global genomic surveillance is needed.

Acknowledgements

We thank the patients for their contribution to this study. This work was supported by a grant from the Health Institutes of Turkey (TUSEB Grant No: 8799).

Author contributions

Conceptualization, L.D., G.D.D, I.K.; Data, T.K.A., N.B.A., M.A., N.D.C., A.S.O., N.A., A.I., Y.K.D., O.A.D.; Clinical sample management, T.K.A., N.B.A., P.Z., G.A., J.Y., B.K.; High-throughput sequencing, T.K.A., G.A., J.Y., B.K.; Analysis, I.K., P.Z.; Writing - Original Draft, I.K.; Writing - Review & Editing, I.K., N.B.A., L.D., G.D.D.

Declaration of interests

The authors declare no competing interests.

Tables

Table 1: Demographic and clinical characteristics of 184 COVID-19 patients.

Age (years, mean $\pm$ SD)	49.7 $\pm$ 19.5
Male gender (n, %)	100 (54.3 %)
Co-existing condition (n, %)	
Hypertension	39 (21.5 %)

Diabetes	38 (22.1 %)
Heart disease	11 (6.4 %)
COPD	16 (9.3 %)
Symptoms (n, %)	
Yes	161 (92 %)
No	14 (8 %)
Chest CT findings (n, %)	
Normal	35 (23.5 %)
Mild	59 (39.6 %)
Severe	42 (28.2 %)
Critical	13 (8.7 %)
Clinical severity (n, %)	
Asymptomatic	14 (8 %)
Mild	128 (73.1 %)
Severe	33 (18.9 %)
ICU (n, %)	
Yes	19 (10.8 %)
No	157 (89.2 %)
Death (n, %)	
Yes	12 (6.9 %)
No	163 (93.1 %)
Biochemical parameters	
Leukocyte count ($\times 10^9$, normal range: 4,000-10,000)	5928,76 $\pm$ 2344,74
Lymphocyte count ($\times 10^9$, normal range: 700 - 4,000)	1733,70 $\pm$ 775,68
C-reactive protein (mg/dL, normal range: 0 - 0.5)	3,91 $\pm$ 5,61
Lactate dehydrogenase (U/L, normal range: 125 - 220)	341,28 $\pm$ 146,45

D-dimer (ng/ml, normal range: 0 - 500)	1123,23 ± 1245,39
Ferritin (ng/ml, normal ranges female:5-204, male: 22-275)	572,94 ± 843,78

Table 2: The most common mutations and amino acid changes in SARS-CoV-2 genomes identified in this study.

Position	Percentage in all samples	Change	Effect	Gene / Region	Amino acid change
241	97.2 %	C /T	Non-coding	ORF1a	NA
23403	97.2 %	A /G	missense	S	D/G
3037	96.1 %	C /T	synonymous	ORF1a	F/F
14408	95.6 %	C /T	missense	ORF1b	P/L
28881-28882	61.4 %	GG/AA	missense	N	R/K
28883	60.8 %	G /C	missense	N	G/R
12809	30.9 %	C /T	missense	ORF1a	L/F
25563	27.6 %	G/T	missense	ORF3a	Q/H
18877	25.5 %	C/T	synonymous	ORF1b	L/L
19839	23.3 %	T/C	synonymous	ORF1b	N/N

Table 3: Selected SARS-CoV-2 variants in the study and two-sided Fisher's exact test results.

Nucleotide position and change	Effect	p-value			
		Gender	Manifest symptoms	Clinical grade (Mild vs Severe)	ICU need
2113:C>T (ORF1ab:p.I616I)	syn	0.6669	1.0000	0.5715	0.3182
3037:C>T (ORF1ab:p.F924F)	syn	1.0000	1.0000	1.0000	0.6017
5730:C>T (ORF1ab:p.T1822I)	non-syn	0.5523	0.5365	0.6890	1.0000
12809:C>T (ORF1ab:p.L4182F)	non-syn	0.0532	1.0000	0.6756	0.6106

14408:C>T (ORF1ab:p.P4715L)	non-syn	1.0000	1.0000	1.0000	0.6034
17104:C>T (ORF1ab:p.H5614Y)	non-syn	1.0000	0.6021	0.4621	1.0000
17690:C>T (ORF1ab:p.S5809L)	non-syn	0.0507	0.5275	0.1587	0.2505
18877:C>T (ORF1ab:p.L6205L)	syn	0.0891	0.3558	0.8204	0.7844
19839:T>C (ORF1ab:p.N6525N)	syn	0.7266	0.3215	0.1073	0.7754
20629:C>T (ORF1ab:p.H6789Y)	non-syn	0.7733	1.0000	0.4616	1.0000
23403:A>G (S:p.D614G)	non-syn	0.7291	1.0000	1.0000	1.0000
25563:G>T (ORF3a:p.Q57H)	non-syn	0.0472	0.7623	0.6556	0.7839
25611:C>A (ORF3a:p.L73L)	syn	1.0000	1.0000	0.2739	0.6354
28881-28883:GGG>AAC (N:p.RG203-204KR)	non-syn	0.0236	0.5701	0.4323	1.0000

Table 4: Amounts of intra-host and consensus mutation events among all 184 samples and their functional effects. AF: intra-host allelic frequency of the variant.

	Intra-host mutation events (10% < AF < 90%)	Consensus mutations (AF > 90%)	p-value
Non-synonymous	469	857	1.0000
Synonymous	317	526	0.2621
Insertion and deletion	46	15	<0.0001
Stop-gain	11	2	0.0004
Non-coding	35	201	0.0001

Figure 1: Phylogenetic tree of 184 viral genomes in this study together with mutations and their annotations.

References

- Alm, E., Broberg, E.K., Connor, T., Hodcroft, E.B., Komissarov, A.B., Maurer-Stroh, S., Melidou, A., Neher, R.A., O'Toole, A., Pereyaslov, D., et al. (2020). Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to June 2020. *Euro Surveill.* 25(32). Published online 2020/08/15 DOI: 10.2807/1560-7917.ES.2020.25.32.2001410.
- Andrews, S., 2010. FastQC: A Quality Control Tool for High Throughput Sequence Data. Available online at: <http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>.
- Becerra-Flores, M., and Cardozo, T. (2020). SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate. *Int J Clin Pract.* 74(8), e13525. Published online 2020/05/07 DOI: 10.1111/ijcp.13525.
- Di Giorgio, S., Martignano, F., Torcia, M.G., Mattiuz, G., and Conticello, S.G. (2020). Evidence for host-dependent RNA editing in the transcriptome of SARS-CoV-2. *Sci Adv.* 6(25), eabb5813. Published online 2020/07/01 DOI: 10.1126/sciadv.abb5813.
- Duffy, S. (2018). Why are RNA virus mutation rates so damn high? *PLoS Biol.* 16(8), e3000003. Published online 2018/08/14 DOI: 10.1371/journal.pbio.3000003.
- Fauver, J.R., Petrone, M.E., Hodcroft, E.B., Shioda, K., Ehrlich, H.Y., Watts, A.G., Vogels, C.B.F., Brito, A.F., Alpert, T., Muyombwe, A., et al. (2020). Coast-to-Coast Spread of SARS-CoV-2 during the Early Epidemic in the United States. *Cell.* 181(5), 990-996 e995. Published online 2020/05/11 DOI: 10.1016/j.cell.2020.04.021.
- Grubaugh, N.D., Gangavarapu, K., Quick, J., Matteson, N.L., De Jesus, J.G., Main, B.J., Tan, A.L., Paul, L.M., Brackney, D.E., Grewal, S., et al. (2019). An amplicon-based sequencing framework for accurately measuring intrahost virus diversity using PrimalSeq and iVar. *Genome Biol.* 20(1), 8. Published online 2019/01/10 DOI: 10.1186/s13059-018-1618-7.
- Grubaugh, N.D., Hanage, W.P., and Rasmussen, A.L. (2020). Making Sense of Mutation: What D614G Means for the COVID-19 Pandemic Remains Unclear. *Cell.* 182(4), 794-795. Published online 2020/07/23 DOI: 10.1016/j.cell.2020.06.040.
- Harris, R.S., and Dudley, J.P. (2015). APOBECs and virus restriction. *Virology.* 479-480, 131-145. Published online 2015/03/31 DOI: 10.1016/j.virol.2015.03.012.
- Hou, Y.J., Chiba, S., Halfmann, P., Ehre, C., Kuroda, M., Dinnon, K.H., 3rd, Leist, S.R., Schafer, A., Nakajima, N., Takahashi, K., et al. (2020). SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. *Science.* Published online 2020/11/14 DOI: 10.1126/science.abe8499.
- Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 395(10223), 497-506. Published online 2020/01/28 DOI: 10.1016/S0140-6736(20)30183-5.
- Initiative, C.-H.G. (2020). The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2

353 virus pandemic. *Eur J Hum Genet.* 28(6), 715-718. Published online 2020/05/15 DOI:
354 10.1038/s41431-020-0636-6.

355 Jordan, R.E., Adab, P., and Cheng, K.K. (2020). Covid-19: risk factors for severe disease and
356 death. *BMJ.* 368, m1198. Published online 2020/03/29 DOI: 10.1136/bmj.m1198.

357 Karacan, I., Akgun, T.K., Agaoglu, N.B., Irvem, A., Alkurt, G., Yildiz, J., Kose, B., Ozel,
358 A.S., Altunal, L.N., Can, N.D., et al. (2020). The origin of SARS-CoV-2 in Istanbul:
359 Sequencing findings from the epicenter of the pandemic in Turkey. *North Clin Istanbul.* 7(3),
360 203-209. Published online 2020/06/02 DOI: 10.14744/nci.2020.90532.

361 Katoh, K., Rozewicki, J., and Yamada, K.D. (2019). MAFFT online service: multiple
362 sequence alignment, interactive sequence choice and visualization. *Brief Bioinform.* 20(4),
363 1160-1166. Published online 2017/10/03 DOI: 10.1093/bib/bbx108.

364 Korber, B., Fischer, W.M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner,
365 N., Giorgi, E.E., Bhattacharya, T., Foley, B., et al. (2020). Tracking Changes in SARS-CoV-
366 2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. *Cell.* 182(4),
367 812-827 e819. Published online 2020/07/23 DOI: 10.1016/j.cell.2020.06.043.

368 Luring, A.S., and Andino, R. (2010). Quasispecies theory and the behavior of RNA viruses.
369 *PLoS Pathog.* 6(7), e1001005. Published online 2010/07/28 DOI:
370 10.1371/journal.ppat.1001005.

371 Li, H. (2011). A statistical framework for SNP calling, mutation discovery, association
372 mapping and population genetical parameter estimation from sequencing data.
373 *Bioinformatics.* 27(21), 2987-2993. Published online 2011/09/10 DOI:
374 10.1093/bioinformatics/btr509.

375 Li, H. (2013). Aligning sequence reads, clone sequences and assembly contigs with BWA-
376 MEM. *arXiv preprint arXiv:1303.3997*.

377 Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis,
378 G., Durbin, R., and Genome Project Data Processing, S. (2009). The Sequence
379 Alignment/Map format and SAMtools. *Bioinformatics.* 25(16), 2078-2079. Published online
380 2009/06/10 DOI: 10.1093/bioinformatics/btp352.

381 Li, Q., Wu, J., Nie, J., Zhang, L., Hao, H., Liu, S., Zhao, C., Zhang, Q., Liu, H., Nie, L., et al.
382 (2020). The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and
383 Antigenicity. *Cell.* 182(5), 1284-1294 e1289. Published online 2020/07/31 DOI:
384 10.1016/j.cell.2020.07.012.

385 Li, X., Xu, S., Yu, M., Wang, K., Tao, Y., Zhou, Y., Shi, J., Zhou, M., Wu, B., Yang, Z., et
386 al. (2020). Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. *J*
387 *Allergy Clin Immunol.* 146(1), 110-118. Published online 2020/04/16 DOI:
388 10.1016/j.jaci.2020.04.006.

389 Liu, Q., Zhao, S., Shi, C.M., Song, S., Zhu, S., Su, Y., Zhao, W., Li, M., Bao, Y., Xue, Y., et
390 al. (2020). Population Genetics of SARS-CoV-2: Disentangling Effects of Sampling Bias and
391 Infection Clusters. *Genomics Proteomics Bioinformatics.* Published online 2020/07/15 DOI:
392 10.1016/j.gpb.2020.06.001.

393 Mangeat, B., Turelli, P., Caron, G., Friedli, M., Perrin, L., and Trono, D. (2003). Broad
394 antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse
395 transcripts. *Nature*. 424(6944), 99-103. Published online 2003/06/17 DOI:
396 10.1038/nature01709.

397 Martin, M. (2011). Cutadapt removes adapter sequences from high-throughput sequencing
398 reads. 2011. 17(1), 3. Published online 2011-08-02 DOI: 10.14806/ej.17.1.200.

399 Matyasek, R., and Kovarik, A. (2020). Mutation Patterns of Human SARS-CoV-2 and Bat
400 RaTG13 Coronavirus Genomes Are Strongly Biased Towards C>U Transitions, Indicating
401 Rapid Evolution in Their Hosts. *Genes (Basel)*. 11(7). Published online 2020/07/11 DOI:
402 10.3390/genes11070761.

403 Mavian, C., Pond, S.K., Marini, S., Magalis, B.R., Vandamme, A.M., Dellicour, S., Scarpino,
404 S.V., Houldcroft, C., Villabona-Arenas, J., Paisie, T.K., et al. (2020). Sampling bias and
405 incorrect rooting make phylogenetic network tracing of SARS-COV-2 infections unreliable.
406 *Proc Natl Acad Sci U S A*. 117(23), 12522-12523. Published online 2020/05/10 DOI:
407 10.1073/pnas.2007295117.

408 Minskaia, E., Hertzog, T., Gorbalenya, A.E., Campanacci, V., Cambillau, C., Canard, B., and
409 Ziebuhr, J. (2006). Discovery of an RNA virus 3'->5' exoribonuclease that is critically
410 involved in coronavirus RNA synthesis. *Proc Natl Acad Sci U S A*. 103(13), 5108-5113.
411 Published online 2006/03/22 DOI: 10.1073/pnas.0508200103.

412 Rose, R., Nolan, D.J., Moot, S., Feehan, A., Cross, S., Garcia-Diaz, J., and Lamers, S.L.
413 (2020). Intra-host site-specific polymorphisms of SARS-CoV-2 is consistent across multiple
414 samples and methodologies. *medRxiv*. 2020.2004.2024.20078691. DOI:
415 10.1101/2020.04.24.20078691.

416 Simmonds, P. (2020). Rampant C->U Hypermutation in the Genomes of SARS-CoV-2 and
417 Other Coronaviruses: Causes and Consequences for Their Short- and Long-Term
418 Evolutionary Trajectories. *mSphere*. 5(3). Published online 2020/06/26 DOI:
419 10.1128/mSphere.00408-20.

420 Snijder, E.J., Bredenbeek, P.J., Dobbe, J.C., Thiel, V., Ziebuhr, J., Poon, L.L., Guan, Y.,
421 Rozanov, M., Spaan, W.J., and Gorbalenya, A.E. (2003). Unique and conserved features of
422 genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2
423 lineage. *J Mol Biol*. 331(5), 991-1004. Published online 2003/08/21 DOI: 10.1016/s0022-
424 2836(03)00865-9.

425 van Dorp, L., Richard, D., Tan, C.C.S., Shaw, L.P., Acman, M., and Balloux, F. (2020). No
426 evidence for increased transmissibility from recurrent mutations in SARS-CoV-2. *Nat*
427 *Commun*. 11(1), 5986. Published online 2020/11/27 DOI: 10.1038/s41467-020-19818-2.

428 Volz, E., Hill, V., McCrone, J.T., Price, A., Jorgensen, D., O'Toole, A., Southgate, J.,
429 Johnson, R., Jackson, B., Nascimento, F.F., et al. (2020). Evaluating the Effects of SARS-
430 CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity. *Cell*. Published online
431 2020/12/05 DOI: 10.1016/j.cell.2020.11.020.

432 Wang, K., Li, M., and Hakonarson, H. (2010). ANNOVAR: functional annotation of genetic
433 variants from high-throughput sequencing data. *Nucleic Acids Res.* 38(16), e164. Published
434 online 2010/07/06 DOI: 10.1093/nar/gkq603.

435 Wu, Z., and McGoogan, J.M. (2020). Characteristics of and Important Lessons From the
436 Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314
437 Cases From the Chinese Center for Disease Control and Prevention. *JAMA.* 323(13), 1239-
438 1242. Published online 2020/02/25 DOI: 10.1001/jama.2020.2648.

439 Zeberg, H., and Paabo, S. (2020). The major genetic risk factor for severe COVID-19 is
440 inherited from Neanderthals. *Nature.* 587(7835), 610-612. Published online 2020/10/01 DOI:
441 10.1038/s41586-020-2818-3.

442 Zhang, X., Tan, Y., Ling, Y., Lu, G., Liu, F., Yi, Z., Jia, X., Wu, M., Shi, B., Xu, S., et al.
443 (2020). Viral and host factors related to the clinical outcome of COVID-19. *Nature.*
444 583(7816), 437-440. Published online 2020/05/21 DOI: 10.1038/s41586-020-2355-0.

445 Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et
446 al. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in
447 Wuhan, China: a retrospective cohort study. *Lancet.* 395(10229), 1054-1062. Published
448 online 2020/03/15 DOI: 10.1016/S0140-6736(20)30566-3.
449